IRMD — Stock Film
STOCK FILMSCENE 1/11IRMD · $87.85
Stock Expert AI presents
IRMD
IRadimed Corporation
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
IRadimed Corporation. A quick introduction.

On the stock market since 2014, it operates in the world of health and science. It has 166 employees. Now — the numbers.

on the stock market since 2014
166 employees
$1.2B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $27 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 27%

This is an established company with proven profits.

THE SALES TREND
Sales are growing, year after year.

Average growth of 19% a year over the last 4 years. Every year shown ended in profit.

$41.8M
2021
$53.3M
2022
$65.6M
2023
$73.2M
2024
$83.8M
2025
Cash on hand:
$0
Total debt:
$0
The cash outweighs the debt.

If every debt were paid off today, $51.2M would still be left in the vault — a solid cushion for hard times.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
96
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
98
very strong

Debt is low and cash is strong; the finances stand solid.

VALUATION
61
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
89
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
43
weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 5 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
Few are betting against it10/10
WEAK SPOTS
Little set aside for the future2/10
Executives aren’t buying3/10
The stock has lost its spark3/10
WORTH WATCHING

R&D Investment: Spending on future research is low.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 16% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
A fat but narrowing margin

The net profit margin is 27% — still a thick cushion, though costs have been eating into it lately.

2
THE BRIGHT SIDE · 2/3
Sales keep climbing

Over the last 3 years, sales grew about 16% a year on average.

3
THE BRIGHT SIDE · 3/3
Strong cash, light debt

There is $51.2M in the vault; even if every debt were paid off, $51.2M would remain.

1
THE RISKS · 1/2
A rich price tag

The company’s market value is 52 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/2
Executives lean toward selling

Over the last 12 months, executives reported 146 sells against just 17 buys. Not an alarm bell by itself, but a number worth watching.

FINALE · THE GRADE
A
0 / 100 · MoonshotScore

On our five-subject report card, IRMD sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: IRMD is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film